冻干粉 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes appear in earlier literature |
| Purity specification | Usually 95% or higher by HPLC area | Research-grade lots are often 98% or higher |
| Solution storage | 2–8 °C, protected from light | Short term; avoid repeated freeze-thaw cycles |
| Dry powder storage | −20 °C or below, desiccated | Protected from moisture and light |
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
1989–1991 – 1.3 L (1,323 cc) B3, 1 barrel, 8-valve, 76 PS (56 kW) / 101 N⋅m (74 lb⋅ft) 1991–1994 – 1.3 L (1,323 cc) B3, EGI-S, 8-valve, 79 PS (58 kW) / 103 N⋅m (76 lb⋅ft) 1989–1991 – 1.5 L (1,498 cc) B5-M, carburetor, 16-valve, 91 PS (67 kW) / 122 N⋅m (90 lb⋅ft) 1990–1994 – 1.5 L (1,498 cc) B5-MI, EGI-S, 16-valve 94 PS (69 kW) / 123 N⋅m (91 lb⋅ft) 1989–1991 – 1.5 L (1,498 cc) B5-DE, EFi, 16-valve DOHC, 110 PS (81 kW) / 127 N⋅m (94 lb⋅ft) 1991–1994 – 1.5 L (1,498 cc) B5-DE, EFi, 16-valve DOHC, 115–120 PS (85–88 kW) / 132 N⋅m (97 lb⋅ft) (lower power for AT cars) 1989–1991 – 1.6 L (1,597 cc) B6, 1 barrel, 8-valve, 85 hp (63 kW; 86 PS) / 92 lb⋅ft (125 N⋅m) 1989–1994 – 1.6 L (1,597 cc) B6, carburetor, 16-valve, SOHC, 103 hp (77 kW; 104 PS) / 108 lb⋅ft (146 N⋅m) 1989–1994 – 1.8 L (1,839 cc) BP, FI, 16-valve DOHC, 140 hp (104 kW; 142 PS) / 118 lb⋅ft (160 N⋅m) 1989–1994 – 1.8 L (1,839 cc) BPT, FI, 16-valve DOHC, turbo, 180 PS (132 kW) / 237 N⋅m (175 lb⋅ft) (Familia GT-X) 1991–1994 – 1.8 L (1,839 cc) B8, FI, 16-valve SOHC, 103 hp (77 kW) 1992–1993 – 1.8 L (1,839 cc) BPD, FI, 16-valve DOHC, turbo, 210 PS (154 kW) / 255 N⋅m (188 lb⋅ft) (Familia GT-R & GT-Ae) 1989–1994 – 1.7 L (1,720 cc) PN, Diesel, 8-valve, 57 PS (42 kW) / 112 N⋅m (83 lb⋅ft) (European specs)
A 2.45 GHz, 6.5 kW source will heat the brain of a 30 g mouse to 90 °C in about 325 milliseconds; a 915 MHz, 25 kW source will heat the brain of a 300 g rat to the same temperature in a second. Special devices designed or modified for this purpose have to be used; use of kitchen-grade microwave ovens is condemned.
Cns1 is a oxidoreductase/dehydrogenase. Cns2 is a HDc-family metal-dependent phosphohydrolase. There is a binding interaction between Cns1 and Cns2. Cns3 is a bifunctional protein. It has an N-terminal (9–101 aa) nucleoside/nucleotide kinase (NK) domain and a C-terminal (681-851 aa) HisG-family ATP phosphoribosyltransferase domain. Cns4 is an ABC transporter, specifically of the putative pleiotropic drug resistance (PDR) family. To produce cordycepin:
In most people, the trails of the burrowing mites are linear or S-shaped tracks in the skin, often accompanied by rows of small, pimple-like mosquito or insect bites. Lesions are symmetrical and mainly affect the hands, wrists, axillae, thighs, buttocks, waist, soles of the feet, areola, and vulva in females, and penis and scrotum in males. The neck and above are usually not affected, except in cases of crusted scabies and infestations of infants, the elderly, and the immunocompromised. Symptoms typically appear two to six weeks after infestation for individuals never before exposed to scabies. For those having been previously exposed, the symptoms can appear within several days after infestation. However, symptoms may appear after several months or years.
Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabologens. Professor Marshall Urist and Professor Hari Reddi discovered their ability to induce the formation of bone and cartilage, BMPs are now considered to constitute a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. The important functioning of BMP signals in physiology is emphasized by the multitude of roles for dysregulated BMP signalling in pathological processes. Cancerous disease often involves misregulation of the BMP signalling system. Absence of BMP signalling is, for instance, an important factor in the progression of colon cancer, and conversely, overactivation of BMP signalling following reflux-induced esophagitis provokes Barrett's esophagus and is thus instrumental in the development of esophageal adenocarcinoma. Recombinant human BMPs (rhBMPs) are used in orthopedic applications such as spinal fusions, nonunions, and oral surgery. rhBMP-2 and rhBMP-7 are Food and Drug Administration (FDA)-approved for some uses. rhBMP-2 causes more overgrown bone than any other BMPs and is widely used off-label.
Sources: en.wikipedia.org
Pregnant women are advised to pay attention to the foods they eat during pregnancy to reduce the risk of exposure to substances or bacteria that may be harmful to the developing fetus. This can include potentially harmful pathogens such as listeria, toxoplasmosis, and salmonella. Intake of large amounts of retinol has been linked to birth defects and abnormalities. During pregnancy, a woman's mass increases by about 12 kg (26 lb). The European Food Safety Authority recommends an increase of 300 mL per day compared to the normal intake for non-pregnant women, taking the total adequate water intake (from food and fluids) to 2,300 mL, or approximately 1,850 mL/ day from fluids alone.
There have been a variety of long-overlap-based assembly methods developed in recent years. One of the most commonly used methods, the Gibson assembly method, was developed in 2009, and provides a one-pot DNA assembly method that does not require the use of restriction enzymes or integrases. Other similar overlap-based assembly methods include Circular Polymerase Extension Cloning (CPEC), Sequence and Ligase Independent Cloning (SLIC) and Seamless Ligation Cloning Extract (SLiCE). Despite the presence of many overlap assembly methods, the Gibson assembly method is still the most popular. Besides the methods listed above, other researchers have built on the concepts used in Gibson assembly and other assembly methods to develop new assembly strategies like the Modular Overlap-Directed Assembly with Linkers (MODAL) strategy, or the Biopart Assembly Standard for Idempotent Cloning (BASIC) method.
The writer finds himself fighting for survival against zombies, going through the church grounds, passing a swamp, running in a volcano rift (called Devil's rift), driving a train through tracks full of zombies, and finally getting into the town, where finds the BMRF radio station and the police station, his main destination. To make things worse, the police who have been sent to investigate the strange happenings have also been turned into zombies and are still capable of using weapons and equipment, and prove to be a constant threat (as well as a source of ammunition). Once the player gets into town, he uses the local radio station to call for the state police. In the end, the player is captured by the undead sheriff and imprisoned. The episode ends with a zombie approaching his cell door to eat him.
Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.
Removing water slows hydrolysis and limits aggregation, so dry powder retains its quality attributes longer than a solution. Suppliers define a shelf life and retest date for the dried form at specified temperatures. Once dissolved, the practical working lifetime shortens considerably.
It generally lists appearance, identity by mass, purity by chromatography, water or residual solvent content, and the methods used. Storage recommendations and a retest date are commonly included. Values are reported against a supplier specification rather than a single universal standard.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.